<SEC-DOCUMENT>0001021408-25-004365.txt : 20250829
<SEC-HEADER>0001021408-25-004365.hdr.sgml : 20250829
<ACCEPTANCE-DATETIME>20250829100900
ACCESSION NUMBER:		0001021408-25-004365
CONFORMED SUBMISSION TYPE:	N-PX
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20250630
FILED AS OF DATE:		20250829
EFFECTIVENESS DATE:		20250829

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GILEAD SCIENCES, INC.
		CENTRAL INDEX KEY:			0000882095
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				943047598
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		N-PX
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	028-25078
		FILM NUMBER:		251277059

	BUSINESS ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6505743000

	MAIL ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GILEAD SCIENCES INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>N-PX
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?>
<edgarSubmission xmlns:com="http://www.sec.gov/edgar/common" xmlns="http://www.sec.gov/edgar/npx">
  <headerData>
    <submissionType>N-PX</submissionType>
    <filerInfo>
      <registrantType>IM</registrantType>
      <liveTestFlag>LIVE</liveTestFlag>
      <filer>
        <issuerCredentials>
          <cik>0000882095</cik>
          <ccc>XXXXXXXX</ccc>
        </issuerCredentials>
      </filer>
      <flags>
        <overrideInternetFlag>false</overrideInternetFlag>
        <confirmingCopyFlag>false</confirmingCopyFlag>
      </flags>
      <periodOfReport>06/30/2025</periodOfReport>
    </filerInfo>
  </headerData>
  <formData>
    <coverPage>
      <yearOrQuarter>YEAR</yearOrQuarter>
      <reportCalendarYear>2025</reportCalendarYear>
      <reportingPerson>
        <name>Gilead Sciences, Inc.</name>
        <phoneNumber>650-574-3000</phoneNumber>
        <address>
          <com:street1>333 Lakeside Drive</com:street1>
          <com:city>Foster City</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94404</com:zipCode>
        </address>
      </reportingPerson>
      <agentForService>
        <name>Andrew D. Dickinson</name>
        <address>
          <com:street1>333 Lakeside Drive</com:street1>
          <com:city>Foster City</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94404</com:zipCode>
        </address>
      </agentForService>
      <reportInfo>
        <reportType>INSTITUTIONAL MANAGER VOTING REPORT</reportType>
        <confidentialTreatment>N</confidentialTreatment>
      </reportInfo>
      <fileNumber>028-25078</fileNumber>
      <explanatoryInformation>
        <explanatoryChoice>N</explanatoryChoice>
      </explanatoryInformation>
    </coverPage>
    <summaryPage>
      <otherIncludedManagersCount>0</otherIncludedManagersCount>
    </summaryPage>
    <signaturePage>
      <reportingPerson>Gilead Sciences, Inc.</reportingPerson>
      <txSignature>Andrew D. Dickinson</txSignature>
      <txPrintedSignature>Andrew D. Dickinson</txPrintedSignature>
      <txTitle>Executive Vice President and Chief Financial Officer</txTitle>
      <txAsOfDate>08/26/2025</txAsOfDate>
    </signaturePage>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>PROXY VOTING RECORD
<SEQUENCE>2
<FILENAME>proxyvote.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<inf:proxyVoteTable xmlns:inf="http://www.sec.gov/edgar/document/npxproxy/informationtable">
  <inf:proxyTable>
    <inf:issuerName>Allogene Therapeutics, Inc.</inf:issuerName>
    <inf:cusip>019770106</inf:cusip>
    <inf:meetingDate>06/18/2025</inf:meetingDate>
    <inf:voteDescription>To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.</inf:voteDescription>
    <inf:voteCategories>
      <inf:voteCategory>
        <inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType>
      </inf:voteCategory>
    </inf:voteCategories>
    <inf:sharesVoted>1156689</inf:sharesVoted>
    <inf:sharesOnLoan>0</inf:sharesOnLoan>
    <inf:vote>
      <inf:voteRecord>
        <inf:howVoted>FOR</inf:howVoted>
        <inf:sharesVoted>1156689</inf:sharesVoted>
        <inf:managementRecommendation>FOR</inf:managementRecommendation>
      </inf:voteRecord>
    </inf:vote>
  </inf:proxyTable>
  <inf:proxyTable>
    <inf:issuerName>Leap Therapeutics, Inc.</inf:issuerName>
    <inf:cusip>52187K200</inf:cusip>
    <inf:meetingDate>06/18/2025</inf:meetingDate>
    <inf:voteDescription>To consider and act upon, by a non-binding advisory vote, a resolution to approve the compensation of our named executive officers</inf:voteDescription>
    <inf:voteCategories>
      <inf:voteCategory>
        <inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType>
      </inf:voteCategory>
    </inf:voteCategories>
    <inf:sharesVoted>5319148</inf:sharesVoted>
    <inf:sharesOnLoan>0</inf:sharesOnLoan>
    <inf:vote>
      <inf:voteRecord>
        <inf:howVoted>FOR</inf:howVoted>
        <inf:sharesVoted>5319148</inf:sharesVoted>
        <inf:managementRecommendation>FOR</inf:managementRecommendation>
      </inf:voteRecord>
    </inf:vote>
  </inf:proxyTable>
  <inf:proxyTable>
    <inf:issuerName>Merus N.V.</inf:issuerName>
    <inf:cusip>N5749R100</inf:cusip>
    <inf:meetingDate>05/21/2025</inf:meetingDate>
    <inf:voteDescription>Approval, on an advisory&#xA0;(non-binding)&#xA0;basis, of the compensation of Merus N.V.&#x2019;s named executive officers.</inf:voteDescription>
    <inf:voteCategories>
      <inf:voteCategory>
        <inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType>
      </inf:voteCategory>
    </inf:voteCategories>
    <inf:sharesVoted>452547</inf:sharesVoted>
    <inf:sharesOnLoan>0</inf:sharesOnLoan>
    <inf:vote>
      <inf:voteRecord>
        <inf:howVoted>FOR</inf:howVoted>
        <inf:sharesVoted>452547</inf:sharesVoted>
        <inf:managementRecommendation>FOR</inf:managementRecommendation>
      </inf:voteRecord>
    </inf:vote>
  </inf:proxyTable>
  <inf:proxyTable>
    <inf:issuerName>Tango Therapeutics, Inc.</inf:issuerName>
    <inf:cusip>87583X109</inf:cusip>
    <inf:meetingDate>06/05/2025</inf:meetingDate>
    <inf:voteDescription>To approve, on a non-binding, advisory basis, the compensation of our named executive officers.</inf:voteDescription>
    <inf:voteCategories>
      <inf:voteCategory>
        <inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType>
      </inf:voteCategory>
    </inf:voteCategories>
    <inf:sharesVoted>4854443</inf:sharesVoted>
    <inf:sharesOnLoan>0</inf:sharesOnLoan>
    <inf:vote>
      <inf:voteRecord>
        <inf:howVoted>FOR</inf:howVoted>
        <inf:sharesVoted>4854443</inf:sharesVoted>
        <inf:managementRecommendation>FOR</inf:managementRecommendation>
      </inf:voteRecord>
    </inf:vote>
  </inf:proxyTable>
  <inf:proxyTable>
    <inf:issuerName>Tango Therapeutics, Inc.</inf:issuerName>
    <inf:cusip>87583X109</inf:cusip>
    <inf:meetingDate>06/05/2025</inf:meetingDate>
    <inf:voteDescription>Non-binding, advisory vote on the frequency of future non-binding, advisory votes on the compensation of our named executive officers.</inf:voteDescription>
    <inf:voteCategories>
      <inf:voteCategory>
        <inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType>
      </inf:voteCategory>
    </inf:voteCategories>
    <inf:sharesVoted>4854443</inf:sharesVoted>
    <inf:sharesOnLoan>0</inf:sharesOnLoan>
    <inf:vote>
      <inf:voteRecord>
        <inf:howVoted>1 YEAR</inf:howVoted>
        <inf:sharesVoted>4854443</inf:sharesVoted>
        <inf:managementRecommendation>FOR</inf:managementRecommendation>
      </inf:voteRecord>
    </inf:vote>
  </inf:proxyTable>
  <inf:proxyTable>
    <inf:issuerName>Assembly Biosciences, Inc.</inf:issuerName>
    <inf:cusip>045396207</inf:cusip>
    <inf:meetingDate>06/05/2025</inf:meetingDate>
    <inf:voteDescription>Approval, on a non-binding advisory basis, of our named executive officers' compensation.</inf:voteDescription>
    <inf:voteCategories>
      <inf:voteCategory>
        <inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType>
      </inf:voteCategory>
    </inf:voteCategories>
    <inf:sharesVoted>2209471</inf:sharesVoted>
    <inf:sharesOnLoan>0</inf:sharesOnLoan>
    <inf:vote>
      <inf:voteRecord>
        <inf:howVoted>FOR</inf:howVoted>
        <inf:sharesVoted>2209471</inf:sharesVoted>
        <inf:managementRecommendation>FOR</inf:managementRecommendation>
      </inf:voteRecord>
    </inf:vote>
  </inf:proxyTable>
  <inf:proxyTable>
    <inf:issuerName>Arcus Biosciences, Inc.</inf:issuerName>
    <inf:cusip>03969F109</inf:cusip>
    <inf:meetingDate>06/10/2025</inf:meetingDate>
    <inf:voteDescription>To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive officers, as disclosed in the Proxy Statement.</inf:voteDescription>
    <inf:voteCategories>
      <inf:voteCategory>
        <inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType>
      </inf:voteCategory>
    </inf:voteCategories>
    <inf:sharesVoted>31424760</inf:sharesVoted>
    <inf:sharesOnLoan>0</inf:sharesOnLoan>
    <inf:vote>
      <inf:voteRecord>
        <inf:howVoted>FOR</inf:howVoted>
        <inf:sharesVoted>31424760</inf:sharesVoted>
        <inf:managementRecommendation>FOR</inf:managementRecommendation>
      </inf:voteRecord>
    </inf:vote>
  </inf:proxyTable>
  <inf:proxyTable>
    <inf:issuerName>Arcellx, Inc.</inf:issuerName>
    <inf:cusip>03940C100</inf:cusip>
    <inf:meetingDate>05/28/2025</inf:meetingDate>
    <inf:voteDescription>To approve, on an advisory basis, the compensation of the named executive officers identified in the 2024 Summary Compensation Table in the "Executive Compensation" section of the proxy statement.</inf:voteDescription>
    <inf:voteCategories>
      <inf:voteCategory>
        <inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType>
      </inf:voteCategory>
    </inf:voteCategories>
    <inf:sharesVoted>6720803</inf:sharesVoted>
    <inf:sharesOnLoan>0</inf:sharesOnLoan>
    <inf:vote>
      <inf:voteRecord>
        <inf:howVoted>FOR</inf:howVoted>
        <inf:sharesVoted>6720803</inf:sharesVoted>
        <inf:managementRecommendation>FOR</inf:managementRecommendation>
      </inf:voteRecord>
    </inf:vote>
  </inf:proxyTable>
  <inf:proxyTable>
    <inf:issuerName>Leap Therapeutics, Inc.</inf:issuerName>
    <inf:cusip>52187K200</inf:cusip>
    <inf:meetingDate>07/02/2024</inf:meetingDate>
    <inf:voteDescription>Advisory vote on executive compensation paid to named executive officers ("Say-on-Pay Proposal").</inf:voteDescription>
    <inf:voteCategories>
      <inf:voteCategory>
        <inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType>
      </inf:voteCategory>
    </inf:voteCategories>
    <inf:sharesVoted>5319148</inf:sharesVoted>
    <inf:sharesOnLoan>0</inf:sharesOnLoan>
    <inf:vote>
      <inf:voteRecord>
        <inf:howVoted>FOR</inf:howVoted>
        <inf:sharesVoted>5319148</inf:sharesVoted>
        <inf:managementRecommendation>FOR</inf:managementRecommendation>
      </inf:voteRecord>
    </inf:vote>
  </inf:proxyTable>
</inf:proxyVoteTable>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
